生物医药领域正在高速发展时期，人源化动物模型已经成为基础科学、药物药效评价、药理研究中不可或缺的工具。百奥赛图制备的一系列人源化小鼠模型，已经成功应用于肿瘤免疫、自身免疫等基础研究及药物开发，频现于各大顶级生物医药领域期刊，获得国内外合作伙伴认可，现在就跟小编一起领略一下他们的风采吧!
文章锦集
4-1BB靶点动物模型
01
文章名称
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes
发表期刊
SCIENCE ADVANCES
发表单位
Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea.
ABL Bio Inc., Seongnam, Republic of Korea.
Department of Life Sciences, POSTECH, Pohang, Republic of Korea.
使用小鼠及肿瘤模型
B-h4-1BB mice, MC38-hB7-H3 tumor
02
文章名称
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
发表期刊
Journal for ImmunoTherapy of Cancer
发表单位
Bicycle Therapeutics, Lexington, Massachusetts, USA
使用小鼠及肿瘤模型
B-hTNFRSF9(CD137) mice, MC38 tumor
03
文章名称
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
发表期刊
Nature Communications
发表单位
Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, 200240 Shanghai, China.
Lyvgen Biopharma,Shanghai, China.
Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China
使用小鼠
B-h4-1BB mice
SIRPα/CD47靶点动物模型
01
文章名称
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
